# Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI

> **NCT06275035** · PHASE3 · RECRUITING · sponsor: **Tata Memorial Centre** · enrollment: 101 (estimated)

## Conditions studied

- Neurocognitive Dysfunction

## Interventions

- **DRUG:** Memantine Oral Tablet

## Key facts

- **NCT ID:** NCT06275035
- **Lead sponsor:** Tata Memorial Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-22
- **Primary completion:** 2026-01
- **Final completion:** 2031-01
- **Target enrollment:** 101 (ESTIMATED)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06275035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06275035, "Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06275035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*